Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma.

Annals of surgical oncology - 1 Apr 2026

Gujarathi Rushabh, Rodman Christopher, Bansal Varun Vivek, Belmont Erika, Setia Namrata, Alpert Lindsay, Hart John, Möller Mecker G, Eng Oliver S, Lee Grace, Polite Blase N, Turaga Kiran K, Shergill Ardaman

Abstract excerpt

BACKGROUND: Findings have linked GNAS-activating mutations, frequent in appendiceal adenocarcinoma (AA), with improved overall survival but poor response to chemotherapy. The authors hypothesized that GNAS-activating mutations are associated with differential outcomes in AA treated with chemotherapy. METHODS: Patients seen at the authors' center between 2013 and 2023 who received systemic chemotherapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Chromogranins

Share to Fluorouracil

Share to GTP-Binding Protein alpha Subunits, Gs

Share to Neoplasm Recurrence, Local

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 41634519
DOI: 10.1245/s10434-025-18805-5
PMCID: PMC12982240

Genes

GNAS
EFS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma.PMID 41634519Read ↗

Genomic Landscape of Appendiceal NeoplasmsSemantic proximity Read ↗

Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.Semantic proximity Read ↗

Mutational profiles and prognostic impact in colorectal and high-grade appendiceal adenocarcinoma with peritoneal metastases.Semantic proximity Read ↗

Mutational signatures in appendiceal adenocarcinomas: potential for future personalization in hyperthermic intraperitoneal chemotherapy?Semantic proximity Read ↗

Molecular Classification of Appendiceal Adenocarcinoma.Semantic proximity Read ↗

Uncovering molecular pathways in appendiceal cancer: A comprehensive characterization for precision oncology.Semantic proximity Read ↗

The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal AdenocarcinomaSemantic proximity Read ↗

Establishing Novel Molecular Subtypes of Appendiceal Cancer.Semantic proximity Read ↗

Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors.Semantic proximity Read ↗

Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H MutationSemantic proximity Read ↗

Targeted Next-Generation Sequencing Improves the Prognostication of Patients with Disseminated Appendiceal Mucinous NeoplasmsSemantic proximity Read ↗

Mutations of the CEACAM5 Gene PELPK Motif in Patients With Appendiceal or Colorectal Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.